Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA.
Gastrointest Endosc. 2021 May;93(5):1019-1033.e5. doi: 10.1016/j.gie.2020.12.014. Epub 2021 Mar 26.
Although molecular analysis of pancreatic cyst fluid may aid pancreatic cyst classification, clinical practice remains highly variable. Therefore, we performed a systematic review and meta-analysis to evaluate the diagnostic performance of KRAS and GNAS mutations in EUS-acquired pancreatic cyst fluid for diagnosis of intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic lesions (MCLs).
Individualized searches were developed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines and meta-analysis analyzed according to the Cochrane Diagnostic Test Accuracy working group methodology. A bivariate model was used to compute the pooled sensitivity and specificity and to plot the summary receiver operating characteristics curve with summary point and corresponding 95% confidence interval (95% CI).
Six studies (785 lesions) were included. For IPMNs and MCLs, KRAS + GNAS (combination) had significantly higher diagnostic accuracy than KRAS alone and GNAS alone (all P < .001). The pooled sensitivity, specificity, and diagnostic accuracy of KRAS + GNAS mutations for diagnosis of IPMNs were 94% (95% CI, 72-99; I = 86.74%), 91% (95% CI, 72-98; I = 89.83), and 97% (95% CI, 95-98), respectively, with each significantly higher compared with carcinoembryonic antigen (CEA) alone (all P < .001). For diagnosis of MCLs, KRAS + GNAS had a similar sensitivity and specificity compared with CEA alone; however, diagnostic accuracy was significantly improved (97% [95% CI, 95-98] vs 89% [95% CI, 86-91]; P < .001).
Molecular analysis for KRAS + GNAS mutations in EUS-acquired pancreatic cyst fluid has high sensitivity and specificity with significantly improved diagnostic accuracy for diagnosis of IPMNs and MCLs when compared with CEA alone.
虽然对胰腺囊液进行分子分析可能有助于胰腺囊的分类,但临床实践仍存在很大差异。因此,我们进行了系统评价和荟萃分析,以评估 EUS 获得的胰腺囊液中 KRAS 和 GNAS 突变对诊断导管内乳头状黏液性肿瘤(IPMNs)和黏液性囊性病变(MCLs)的诊断性能。
根据系统评价和荟萃分析首选报告项目(PRISMA)和观察性研究荟萃分析中的流行病学(MOOSE)指南制定了个体化搜索,并根据 Cochrane 诊断测试准确性工作组方法进行荟萃分析。使用双变量模型计算汇总敏感性和特异性,并绘制汇总受试者工作特征曲线,汇总点和相应的 95%置信区间(95%CI)。
纳入了 6 项研究(785 个病变)。对于 IPMNs 和 MCLs,KRAS + GNAS(联合)的诊断准确性明显高于 KRAS 单独和 GNAS 单独(均 P<.001)。KRAS + GNAS 突变对诊断 IPMNs 的敏感性、特异性和诊断准确性分别为 94%(95%CI,72-99;I=86.74%)、91%(95%CI,72-98;I=89.83%)和 97%(95%CI,95-98),与单独使用癌胚抗原(CEA)相比,均显著更高(均 P<.001)。对于 MCLs 的诊断,KRAS + GNAS 的敏感性和特异性与 CEA 单独使用相似,但诊断准确性显著提高(97%[95%CI,95-98] vs 89%[95%CI,86-91];P<.001)。
与单独使用 CEA 相比,EUS 获得的胰腺囊液中 KRAS + GNAS 突变的分子分析具有较高的敏感性和特异性,对诊断 IPMNs 和 MCLs 的诊断准确性显著提高。